Market Overview

UPDATE: Goldman Sachs Raises PT to $16 on NuVasive


Goldman Sachs raises its price target $2 to $16 on Neutral-rated NuVasive (NASDAQ: NUVA) as the company continues to execute in what is an increasingly difficult end-user market.

Goldman Sachs says, "4Q2011 results showed market share acceleration in the base US Spine business, as share gains and conversion to minimally invasive surgical (MIS) procedures are still positive trends. In 2012, management's guidance assumes that the base organic growth rate decelerates 300bp (US decelerating 400bp), which we think is appropriately conservative as it relates to end-market trends."

NUVA closed at $15.55 a share yesterday.

Posted-In: Goldman SachsAnalyst Color Price Target Reiteration Intraday Update Analyst Ratings


Related Articles (NUVA)

View Comments and Join the Discussion!

Partner Center